Availability and affordability of anticancer medicines in Iran based on WHO/HAI standard survey methods

This publication has 18 references indexed in Scilit:

• Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan
  BMC Cancer, 2018
• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  The Lancet, 2017
• A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
  Oncotarget, 2017
• Survey on the availability, price and affordability of selected essential medicines for non-communicable diseases in community pharmacies of Kathmandu valley
  Sage Open Medicine, 2017
• ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
  Annals of Oncology, 2016
• Cost of treatment for children with acute lymphoblastic leukemia in Bangladesh
  Journal of Cancer Policy, 2015
• Access to Medicines by Seguro Popular Beneficiaries: Pending Tasks towards Universal Health Coverage
  PLOS ONE, 2015
• Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
  European Journal of Cancer, 2013
• Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines
  Journal of Law, Medicine & Ethics, 2012
• Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran
  Eastern Mediterranean Health Journal, 2004